Stereotaxis, Inc. STXS
"our" refer to Stereotaxis, Inc. and its wholly owned subsidiaries. GenesisX RMN®, Genesis RMN®,
Stereotaxis, Inc. All other trademarks that appear in this report are the property of their respective owners.
annual report on Form 10-K, including the sections entitled "Business" and "Management's Discussion and Analysis
to perform certain medical procedures with our products safely, effectively and efficiently;
Last close
1.39
2026-09-04
Market cap
$139.3M
2026-06-30 share count
52-week range
1.24 - 3.59
Valuation FY2025 figures against the last close
P/S4.3x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield0.0%
Diluted EPS-0.25
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $32.4M | $26.9M | $26.8M | $28.1M | $35.0M | $26.6M | $28.9M | $29.3M | $31.1M | $32.2M |
| Cost of revenue | $15.3M | $12.3M | $11.9M | $9.7M | $11.8M | $7.7M | $6.1M | $5.7M | $10.8M | $7.5M |
| Gross profit | $17.1M | $14.6M | $14.9M | $18.5M | $23.2M | $19.0M | $22.8M | $23.6M | $20.4M | $24.6M |
| R&D | $9.4M | $9.8M | $10.3M | $10.6M | $10.2M | $8.1M | $9.0M | $8.2M | $6.7M | $5.5M |
| SG&A | $17.8M | $17.2M | $14.1M | $14.4M | $14.0M | $6.4M | $5.8M | $4.9M | $6.0M | $10.3M |
| Total operating expenses | $39.2M | $39.3M | $36.7M | $37.2M | $36.1M | $25.7M | $27.6M | $26.1M | $26.3M | $31.1M |
| Operating income | -$22.1M | -$24.7M | -$21.8M | -$18.8M | -$12.9M | -$6.7M | -$4.8M | -$2.5M | -$5.9M | -$6.4M |
| Interest expense | $467.0K | $694.0K | $1.1M | $484.0K | $11.0K | $67.4K | $235.6K | $16.6K | $179.8K | $2.5M |
| Net income | -$21.6M | -$24.0M | -$20.7M | -$18.3M | -$10.7M | -$6.6M | -$4.6M | $116.8K | -$5.9M | -$5.3M |
| EPS, basic | -0.25 | -0.30 | -0.27 | -0.26 | -0.16 | -0.11 | -0.10 | -0.03 | -0.32 | -0.54 |
| EPS, diluted | -0.25 | -0.30 | -0.27 | -0.26 | -0.16 | -0.11 | -0.10 | -0.03 | -0.32 | -0.54 |
| Shares, diluted (wtd. avg.) | $91.0M | $85.2M | $80.7M | $76.1M | $75.6M | $72.7M | $63.1M | $52.1M | $22.6M | $21.8M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $13.4M | $12.2M | $19.8M | $8.6M | $40.1M | $43.9M | $30.2M | $10.8M | $3.7M | $8.5M |
| Short-term investments | — | — | — | $19.8M | — | — | — | — | — | — |
| Receivables | $5.8M | $3.8M | $3.8M | $5.1M | $5.4M | $3.5M | $5.3M | $5.0M | $4.3M | $4.7M |
| Inventory | $9.6M | $8.3M | $8.4M | $7.9M | $4.4M | $3.3M | $1.8M | $1.2M | $1.1M | $5.4M |
| Total current assets | $33.8M | $26.4M | $33.3M | $43.2M | $51.4M | $52.7M | $38.8M | $18.0M | $9.9M | $19.4M |
| Property, plant and equipment | $3.0M | $3.6M | $3.3M | $3.8M | $2.6M | $195.1K | $250.4K | $343.7K | $592.7K | $1.1M |
| Goodwill | $3.8M | $3.8M | — | — | — | — | — | — | — | — |
| Other intangibles | $6.4M | $7.4M | — | — | — | — | — | — | $159.5K | $436.6K |
| Total assets | $52.3M | $46.7M | $41.9M | $53.4M | $61.0M | $55.5M | $43.6M | $18.5M | $10.7M | $21.0M |
| Accounts payable | $4.8M | $5.7M | $3.2M | $3.3M | $4.2M | $1.6M | $2.1M | $1.7M | $1.7M | $2.6M |
| Short-term debt | — | — | — | — | — | $1.2M | — | — | — | — |
| Total current liabilities | $22.4M | $21.6M | $13.2M | $14.3M | $13.3M | $13.6M | $12.2M | $10.2M | $30.1M | $35.7M |
| Long-term debt | — | — | — | — | — | $973.3K | — | — | — | — |
| Total liabilities | $33.5M | $35.3M | $20.0M | $21.5M | $21.6M | $15.2M | $15.1M | $11.2M | $31.3M | $36.5M |
| Retained earnings | -$583.4M | -$561.7M | -$537.7M | -$517.0M | -$498.7M | -$488.0M | -$481.3M | -$476.7M | -$477.1M | -$471.2M |
| Total equity | $13.5M | $6.1M | $16.3M | $26.3M | $33.8M | $34.6M | $22.8M | $1.3M | -$26.6M | -$21.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.7M | -$8.5M | -$9.1M | -$8.4M | -$2.9M | -$3.5M | -$4.6M | -$2.5M | -$4.7M | -$6.6M |
| Depreciation and amortisation | $626.0K | $587.0K | $595.0K | $429.0K | $106.0K | $126.2K | $122.7K | $513.0K | $554.4K | $367.6K |
| Stock-based compensation | $9.9M | $10.3M | $10.6M | $10.6M | $9.4M | $3.2M | $1.3M | $561.0K | $768.7K | $1.4M |
| Capital expenditure | $93.0K | $34.0K | $366.0K | $2.4M | $1.4M | $70.9K | $29.5K | $265.5K | $81.6K | $410.2K |
| Investing cash flow | -$93.0K | $74.0K | $19.8M | -$22.1M | -$1.4M | -$70.9K | -$29.5K | -$265.5K | -$81.6K | -$410.2K |
| Financing cash flow | $14.8M | $297.0K | $81.0K | $220.0K | $547.0K | $17.3M | $24.0M | $9.9M | -$58.9K | $9.9M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | — | — | $0 | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-015172.
Others in SIC 3845
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MDT | Medtronic plc | $120.46B | 25.2x | 8.4% |
| LIVN | LivaNova PLC | $4.51B | — | 10.7% |
| ITGR | Integer Holdings Corp | $4.30B | 43.8x | 8.0% |
| TMDX | TransMedics Group, Inc. | $3.12B | 18.5x | 37.1% |
| AXGN | Axogen, Inc. | $2.60B | — | 20.2% |
| BLFS | BIOLIFE SOLUTIONS INC | $1.72B | — | 28.9% |
| CNMD | CONMED Corp | $1.48B | 32.7x | 5.2% |
| CBLL | Ceribell, Inc. | $948.7M | — | 36.1% |